Your browser doesn't support javascript.
loading
Phase 1 study of inotuzumab ozogamicin combined with R-GDP for the treatment of patients with relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma.
Sangha, Randeep; Davies, Andrew; Dang, Nam H; Ogura, Michinori; MacDonald, David A; Ananthakrishnan, Revathi; Paccagnella, M Luisa; Vandendries, Erik; Boni, Joseph; Goh, Yeow Tee.
Afiliação
  • Sangha R; Cross Cancer InstituteEdmontonCanada.
  • Davies A; Cancer Research UK Centre, Somers Cancer Research Building, University of SouthamptonSouthamptonUK.
  • Dang NH; University of FloridaGainesvilleFLUSA.
  • Ogura M; Nagoya Daini Red Cross HospitalNagoyaJapan.
  • MacDonald DA; Tokai Central HospitalKakamigahara, GifuJapan.
  • Ananthakrishnan R; Queen Elizabeth II Health Sciences CenterHalifaxCanada.
  • Paccagnella ML; Inventiv HealthCambridgeMAUSA.
  • Vandendries E; Pfizer IncGrotonCTUSA.
  • Boni J; Pfizer IncCambridgeMAUSA.
  • Goh YT; Pfizer IncCollegevillePAUSA.
J Drug Assess ; 6(1): 10-17, 2017.
Article em En | MEDLINE | ID: mdl-28959500
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: J Drug Assess Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: J Drug Assess Ano de publicação: 2017 Tipo de documento: Article